The exact mechanism by which sirolimus and other mTOR inhibitors contribute to hyperglycemia remains unclear, but it is generally thought that these drugs increase insulin resistance by disrupting cellular signaling pathways. This evidence concerns the gene INS and Hyperglycemia.